Age influences on the molecular presentation of tumours.
Constance H LiSyed HaiderPaul C BoutrosPublished in: Nature communications (2022)
Cancer is often called a disease of aging. There are numerous ways in which cancer epidemiology and behaviour change with the age of the patient. The molecular bases for these relationships remain largely underexplored. To characterise them, we analyse age-associations in the nuclear and mitochondrial somatic mutational landscape of 20,033 tumours across 35 tumour-types. Age influences both the number of mutations in a tumour (0.077 mutations per megabase per year) and their evolutionary timing. Specific mutational signatures are associated with age, reflecting differences in exogenous and endogenous oncogenic processes such as a greater influence of tobacco use in the tumours of younger patients, but higher activity of DNA damage repair signatures in those of older patients. We find that known cancer driver genes such as CDKN2A and CREBBP are mutated in age-associated frequencies, and these alter the transcriptome and predict for clinical outcomes. These effects are most striking in brain cancers where alterations like SUFU loss and ATRX mutation are age-dependent prognostic biomarkers. Using three cancer datasets, we show that age shapes the somatic mutational landscape of cancer, with clinical implications.
Keyphrases
- papillary thyroid
- squamous cell
- dna damage
- genome wide
- lymph node metastasis
- squamous cell carcinoma
- chronic kidney disease
- oxidative stress
- end stage renal disease
- childhood cancer
- young adults
- risk factors
- case report
- dna methylation
- newly diagnosed
- multiple sclerosis
- gene expression
- blood brain barrier
- prognostic factors
- wild type
- patient reported